Comparing Tecan Group (OTCMKTS:TCHBF) & Profound Medical (NASDAQ:PROF)

Profound Medical (NASDAQ:PROF) and Tecan Group (OTCMKTS:TCHBF) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Profound Medical and Tecan Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1	0	1	1	2.67
Tecan Group	0	0	0	0	0.00

Profound Medical currently has a consensus price target of $11.50, suggesting a potential upside of 55.20%. Given Profound Medical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Profound Medical is more favorable than Tecan Group.

Profitability

This table compares Profound Medical and Tecan Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profound Medical	-66.62%	-24.14%	-19.74%
Tecan Group	N/A	N/A	N/A

Insider and Institutional Ownership

47.9% of Profound Medical shares are held by institutional investors. Comparatively, 46.8% of Tecan Group shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Profound Medical and Tecan Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10 million	16.73	-$42.57 million	($1.24)	-5.98
Tecan Group	N/A	N/A	N/A	$4.27	59.03

Tecan Group has lower revenue, but higher earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Tecan Group, indicating that it is currently the more affordable of the two stocks.

Summary

Profound Medical beats Tecan Group on 7 of the 12 factors compared between the two stocks.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

About Tecan Group

Tecan Group AG provides laboratory instruments and solutions for pharmaceutical, biotechnology and in-vitro diagnostic companies, university research departments, and diagnostic and other laboratories. It operates through Life Sciences Business and Partnering Business segments. The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and antibodies, and software; and Tecan Labwerx, an automation solution. It provides PARAMIT, a contract design and manufacturing service. The company operates in Switzerland, Europe, Other European countries, North America, Asia, and internationally. Tecan Group AG was founded in 1980 and is headquartered in Männedorf, Switzerland.